021-51111890
购物车（）
sales@molnova.cn
Lotamilast
CAS No. 947620-48-6
Lotamilast ( RVT 501;E6005 )
产品货号. M16789 CAS No. 947620-48-6
Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥551 | 有现货 |
|
| 5MG | ￥867 | 有现货 |
|
| 10MG | ￥1312 | 有现货 |
|
| 25MG | ￥2406 | 有现货 |
|
| 50MG | ￥4228 | 有现货 |
|
| 100MG | ￥6124 | 有现货 |
|
| 500MG | ￥12798 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Lotamilast
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM.
-
产品描述Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM; produces an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules in mice after topical application; ameliorates the appearance of atopic dermatitis-like skin lesions in AD models.Dermatitis Phase 2 Clinical
-
同义词RVT 501;E6005
-
通路Angiogenesis
-
靶点PDE
-
受体PDE4;PDE-4
-
研究领域Inflammation/Immunology
-
适应症Dermatitis
化学信息
-
CAS Number947620-48-6
-
分子量472.50
-
分子式C26H24N4O5
-
纯度>98% (HPLC)
-
溶解度（ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESO=C(OC)C1=CC=C(C(NC2=CC=CC(C3=C4C=C(OC)C(OC)=CC4=NC(NC)=N3)=C2)=O)C=C1
-
化学全称methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Ishii N, et al. J Pharmacol Exp Ther. 2013 Jul;346(1):105-12.
2. Andoh T, et al. Exp Dermatol. 2014 May;23(5):359-61.
3. Kubota S, et al. Eur J Pharmacol. 2015 Dec 5;768:41-8.
4. Furue M, et al. Expert Opin Investig Drugs. 2017 Dec;26(12):1403-1408.
2. Andoh T, et al. Exp Dermatol. 2014 May;23(5):359-61.
3. Kubota S, et al. Eur J Pharmacol. 2015 Dec 5;768:41-8.
4. Furue M, et al. Expert Opin Investig Drugs. 2017 Dec;26(12):1403-1408.
产品手册
关联产品
-
LJI308
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
Lodenafil
Lodenafil is a potent PDE5 inhibitor with treatment of erectile dysfunction (ED).
-
GSK-256066
A potent, selective PDE4 inhibitor with pIC50 of 11.5, 11.3, 11.4, and 11.9 for PDE4B, A, C, and D, respectively.
